Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05357235
Other study ID # CFH2022-1-2172-2
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2022
Est. completion date December 2024

Study information

Verified date May 2022
Source Beijing Ditan Hospital
Contact Yao Xie, Doctor
Phone 8610-84322200
Email xieyao00120184@sina.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Chronic hepatitis B seriously endangers the health of our people, especially the occurrence of HCC, which brings huge economic burden and life threat to our people. 84% - 92% of HCC in China is related to chronic HBV infection. How to further reduce the risk of liver cancer is an urgent problem to be solved in clinical research and an important direction. Although NAs treatment can make patients achieve the negative transformation of virus, it can not effectively reduce the level of virus antigen, and it also lacks the ability to improve the immune clearance of virus. As a result, the incidence of liver cancer in patients with long-term NA treatment is still 4.5% - 10.5%, and the incidence of HCC in patients with hypoviremia in Na treatment is higher. In current clinical practice, nearly 1 / 3 of patients treated with NAs can not reach the detection line of highly sensitive reagent. It is an important measure to make the patients with hypoviremia and inactive low virus replication treated by NAs below the detection line of highly sensitive reagent and further reduce the risk of HCC. However, it is still not enough to minimize the risk of HCC to achieve a complete viral response only through NA treatment. The long-term follow-up showed that the incidence of HBsAg disappeared by only 2.0% - 0.0% regardless of the long-term treatment of HBsAg. Therefore, the most important measure to minimize the occurrence of HCC is to optimize the treatment of NA treated patients with low virus replication and inactive patients with low virus replication to achieve complete virus response and clinical cure. The purpose of this study is to explore the optimal treatment scheme for chronic hepatitis B NA treated patients with hypoviremia and natural low virus replication patients to significantly reduce the risk of HCC.


Description:

Chronic hepatitis B seriously endangers the health of our people, especially the occurrence of liver cancer, which brings huge economic burden and life threat to our people. 84% - 92% of hepatocellular carcinoma (HCC) in China is related to chronic HBV infection. How to further reduce the risk of liver cancer is an urgent problem to be solved in clinical research and an important direction. Although NAs treatment can make patients achieve the negative transformation of virus, it can not effectively reduce the level of virus antigen, and it also lacks the ability to improve the immune clearance of virus. As a result, the incidence of liver cancer in patients with long-term NA treatment is still 4.5% - 10.5%, and the incidence of HCC in patients with hypoviremia in Na treatment is higher. In current clinical practice, nearly 1 / 3 of patients treated with NAs can not reach the detection line of highly sensitive reagent. It is an important measure to make the patients with hypoviremia and inactive low virus replication treated by NAs below the detection line of highly sensitive reagent and further reduce the risk of HCC. However, it is still not enough to minimize the risk of HCC to achieve a complete viral response only through NA treatment. The long-term follow-up showed that the incidence of HBsAg disappeared by only 2.0% - 0.0% regardless of the long-term treatment of HBsAg. Therefore, the most important measure to minimize the occurrence of HCC is to optimize the treatment of NA treated patients with low virus replication and inactive patients with low virus replication to achieve complete virus response and clinical cure. The purpose of this study is to explore the optimal treatment scheme for chronic hepatitis B Na treated patients with hypoviremia and natural low virus replication patients to significantly reduce the risk of liver cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 1200
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 16 Years to 60 Years
Eligibility Inclusion Criteria: - Aged from 16 to 60; - The positive time of HBsAg was 6 months, - 48 weeks of treatment with ETV, TDF or TAF, including HBeAg positive and negative patients; - High sensitive reagent was used to confirm that the low level of serum HBV DNA was 20 IU / ml-2000 IU / ml. - Good compliance and sign informed consent. Exclusion Criteria: 1. Patients with decompensated liver cirrhosis or previous decompensated liver cirrhosis; 2. Those who have used interferon within 6 months; 3. at the same time, it is associated with other virus infections, such as hepatitis A virus, hepatitis C virus, hepatitis D virus, hepatitis E virus, AIDS virus, etc; 4. in addition to hepatitis B, there are other serious physical and mental diseases, including uncontrolled primary kidney, heart, lung, vascular, neurological, digestive, severe metabolic diseases (such as uncontrolled hyperthyroidism, serious complications of diabetes and adrenal diseases), immune deficiency diseases, and severe infections; 5. Active or suspected malignant tumor or history of malignant tumor; 6. 6 months before enrollment or currently receiving corticosteroids, immunosuppressants and chemotherapeutic drugs; 7. Complicated with alcoholic liver disease, autoimmune liver disease and other liver diseases; 8. HBV resistant patients; 9. Other situations that the researcher believes are not suitable for inclusion. PegIFN a Treatment contraindications: 1. Prohibited for known pairs a- Patients who are allergic to interferon, E. coli products, polyethylene glycol or any component of this product; 2. It is forbidden to be used in patients with autoimmune hepatitis; 3. Pregnant and lactating women; 4. Central nervous system diseases, mental diseases, uncontrolled epilepsy, non withdrawal of alcohol / drug abuse, decompensated liver cirrhosis, symptomatic heart disease, uncontrolled autoimmune diseases and severe thyroid function diseases; 5. Absolute neutrophil count before treatment = 1.0 × 109 / L, platelet = 80 × 109/L?

Study Design


Intervention

Drug:
PEG-IFN
PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks

Locations

Country Name City State
China Department of Hepatology Division 2, Beijing Ditan Hospital Beijing Beijing

Sponsors (3)

Lead Sponsor Collaborator
Beijing Ditan Hospital Beijing 302 Hospital/5th Medical Center of Chinese PLA General Hospital, Beijing YouAn Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of HCC during the project study Once the hepatitis attack (HBV DNA > 2000 IU / ml, ALT >40 U / L) is reached during the observation of inactive low virus replication HBsAg carriers, the researchers will communicate with the patients and take antiviral treatment, and continue to follow-up observation. All enrolled patients were included in the continuous follow-up cohort during the study period and after the end of the project. 48 weeks
Secondary The negative conversion rate of HBV DNA after 48 weeks of treatment was optimized (below the detection line of highly sensitive detection reagent) Once the hepatitis attack (HBV DNA > 2000 IU / ml, ALT >40 U / L) is reached during the observation of inactive low virus replication HBsAg carriers, the researchers will communicate with the patients and take antiviral treatment, and continue to follow-up observation. All enrolled patients were included in the continuous follow-up cohort during the study period and after the end of the project. 48 weeks
Secondary The incidence of HBsAg disappearance during the study period; Once the hepatitis attack (HBV DNA >2000 IU / ml, ALT > 40 U / L) is reached during the observation of inactive low virus replication HBsAg carriers, the researchers will communicate with the patients and take antiviral treatment, and continue to follow-up observation. All enrolled patients were included in the continuous follow-up cohort during the study period and after the end of the project. 48 weeks
Secondary HBeAg seroconversion rate in HBeAg positive patients; Once the hepatitis attack (HBV DNA > 2000 IU / ml, ALT> 40 U / L) is reached during the observation of inactive low virus replication HBsAg carriers, the researchers will communicate with the patients and take antiviral treatment, and continue to follow-up observation. All enrolled patients were included in the continuous follow-up cohort during the study period and after the end of the project. 48 weeks
Secondary Incidence of chronic hepatitis B during the study period Once the hepatitis attack (HBV DNA > 2000 IU / ml, ALT >40 U / L) is reached during the observation of inactive low virus replication HBsAg carriers, the researchers will communicate with the patients and take antiviral treatment, and continue to follow-up observation. All enrolled patients were included in the continuous follow-up cohort during the study period and after the end of the project. 48 weeks
Secondary To study the incidence of complications such as cirrhotic ascites and upper gastrointestinal bleeding during long-term follow-up. Once the hepatitis attack (HBV DNA > 2000 IU / ml, ALT > 40 U / L) is reached during the observation of inactive low virus replication HBsAg carriers, the researchers will communicate with the patients and take antiviral treatment, and continue to follow-up observation. All enrolled patients were included in the continuous follow-up cohort during the study period and after the end of the project. 48 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04496882 - Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue Phase 4
Completed NCT04083716 - A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults Phase 1
Not yet recruiting NCT03038802 - A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Phase 1/Phase 2
Completed NCT05310487 - Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects Phase 1
Recruiting NCT06070051 - Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy Phase 1
Terminated NCT05001022 - A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects Phase 1
Recruiting NCT04139850 - The Establishment of Korean Hepatitis B Patients Cohort
Recruiting NCT05343481 - Efficacy of VTP-300 in Chronic Hepatitis B Infection Phase 2
Not yet recruiting NCT05490836 - Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients N/A
Recruiting NCT04543565 - Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study Phase 3
Active, not recruiting NCT02894918 - A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs Phase 4
Not yet recruiting NCT02793791 - Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients N/A
Recruiting NCT02287857 - Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B N/A
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Recruiting NCT01491295 - Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Phase 4
Terminated NCT01872988 - Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma Phase 3
Recruiting NCT01487876 - Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients Phase 2
Completed NCT01531166 - A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon N/A
Not yet recruiting NCT01436539 - Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Phase 4
Recruiting NCT01360879 - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease N/A